SummitTX Capital’s Protagonist Therapeutics PTGX Stock Holding History

SummitTX Capital’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-42,266	Closed	-$3.69M	–	933
2025 Q4	$3.69M	Buy	42,266 +10,776	+34%	+$882K	0.11%	201
2025 Q3	$2.09M	Buy	+31,490	New	+$1.79M	0.09%	253
2025 Q2	–	Sell	-5,900	Closed	-$285K	–	967
2025 Q1	$285K	Buy	+5,900	New	+$247K	0.01%	669

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

SummitTX Capital's PTGX Position: Q1 2026 in Review

SummitTX Capital sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 42,266 shares — an estimated $3.69M sold.

SummitTX Capital first reported a position in PTGX in Q1 2025 and held it in 3 quarters. The position peaked at $3.69M in Q4 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

SummitTX Capital reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
SummitTX Capital sold 42,266 Protagonist Therapeutics shares in Q1 2026, an estimated $3.69M.
SummitTX Capital first reported a position in Protagonist Therapeutics in Q1 2025 and held it in 3 quarters.
SummitTX Capital's Protagonist Therapeutics position peaked at $3.69M in Q4 2025.
317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.